BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025

BIOCRYST PHARMACEUTICALS INC

Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.
Separation benefits include 1 year base salary, 2025 bonus (actual and target), 12 months health coverage, outplacement, accelerated equity vesting.
Consulting agreement for transition through Dec 31, 2025: monthly fee $12,500, continued equity vesting during period.
No disagreement cited with Board or management regarding company operations or policies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.